Intellectual Property Watch; MSF Challenges Gilead Hepatitis C Patent In China
"According to the [Médecins Sans Frontières (MSF, Doctors Without Borders) press] release, “Gilead launched the sofosbuvir/velpatasvir
combination at a price of US$51,000 for a 12-week treatment course in
the United Kingdom, whereas the same treatment course is available for
as low as $286 in India from generic manufacturers. In China, this
combination was registered in May 2018, but Gilead has not yet announced
its price.”
Showing posts with label Médecins Sans Frontières (MSF) Doctors Without Borders. Show all posts
Showing posts with label Médecins Sans Frontières (MSF) Doctors Without Borders. Show all posts
Subscribe to:
Posts (Atom)